Skip to main content
Premium Trial:

Request an Annual Quote

Life Technologies Acquires Cytonix

NEW YORK (GenomeWeb News) – Life Technologies recently acquired privately held Cytonix, a microfluidics technologies firm, the firm said earlier this week in its second-quarter earnings statement.

Life Technologies provided few details about the acquisition of the Beltsville, Md.-based company. However, it said that it acquired the firm for its intellectual property related to its microfluidics-based digital polymerase chain reaction technology.

Life Technologies also said that it plans to license the technology to partners as well as commercialize new products that can be used for applications ranging from next-generation sequencing library quantification to molecular diagnostic assays.

Last year, Cytonix's wholly-owned subsidiary, Genomic Nanosystems, licensed to Sequenom exclusive rights to use its digital PCR methods for non-invasive, prenatal diagnostic testing and sample analysis on any platform. In addition, Sequenom obtained exclusive rights to use digital PCR in conjunction with mass spectrometry for all commercial, diagnostic, or research applications except second-generation sequencing.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.